Novartis to Present Five-Year (ALITHIOS) Open-Label Extension Study Results of Kesimpta (ofatumumab) for Relapsing Multiple Sclerosis at AAN 2023
- The (ALITHIOS) OLE study evaluating Kesimpta which showed continuous treatment with Kesimpta for ~5yr. was associated with fewer confirmed disability worsening events vs those who switched later from teriflunomide to Kesimpta
- ~80% remained free of 6mos. CDW, low brain volume change over 5yr. favored earlier initiation of Kesimpta, ABVC in the core P-III trials for continuous Kesimpta was -0.34%/yr. vs switch group (-0.42%/yr.) while -0.27%/yr. vs -0.28%/yr. in the extension
- In the separate analysis, the therapy was well-tolerated with no new or increased safety risks, overall rates of AEs & SAEs were consistent with the core P-III trials, IgG levels remained stable @~5yr., treatment interruption/discontinuation due to low lgG & lgM in (0.2% & 10.3%)/ (0.2% & 3.6%) patients
Ref: Novartis | Image: Novartis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.